Action Required: Password Reset on Next Login
As part of our recent security and system improvements, a password reset will be required the next time you log in. This applies to username/password users only; SSO users are not affected.
To reset your password, please visit the Reset Password page.
We appreciate your patience during this transition and are available to assist with any questions. For support, please call us at +1 650-552-4224 or email us at support@biocentury.com.
- Company Profiles
- Target Profiles
- Product Profiles
Explore BCIQ profiles by entering a company name.
Resolution Therapeutics Ltd.
Headquarters: Edinburgh, United Kingdom
Website: https://resolution-tx.com/
Year Founded: 2017
Status: Private
BioCentury | Oct 4, 2024
Management Tracks
Resolution names Paul Sekhri chair
Plus: Dadswell leaving Illumina as general counsel and updates from Eliem, Codexis, Oculis, Illumina, Eupraxia and PharmaJet
BioCentury | Oct 3, 2024
Finance
Kurma investing new fund; Kailera advancing obesity assets with $400M
BioCentury’s latest Venture Report also features news about LoQus23, Aktis, Resolution, Triveni, Flagship and more
BioCentury | Aug 19, 2023
Management Tracks
Burrows leaving Arcutis as CFO
Plus: Resolution names Novartis veteran Hefni as CEO and Cidara hires Davarpanah
BioCentury | May 3, 2023
Management Tracks
Filius to depart Galapagos
Plus: Modis joins Amphista as CSO and updates from ObsEva, CS Genetics, Resolution and Newron
BioCentury | Jul 21, 2022
Management Tracks
Versanis recruits Pruzanski as CEO, adds Maraganore, Duncan to board
Plus BMS’s new pricing SVP and updates from Forbion, Nuvalent and more
BioCentury | Apr 6, 2022
Product Development
April 5 Quick Takes: Short on cash, Bluebird restructures
Plus Pharma 2 B meets in Phase III and updates from Resolution, AstraZeneca and more
BioCentury | Feb 12, 2022
Emerging Company Profile
BioCentury’s 2021 class of emerging cell therapy companies
The 19 newcos are pushing the modality’s frontiers: tapping new cell types, reaching beyond blood cancers and rethinking manufacturing
BioCentury | Jan 26, 2021
Emerging Company Profile
Resolution: Fighting fibrosis with macrophages
Resolution is bringing macrophage cell therapies into the fibrosis arena
BioCentury | Sep 15, 2020
Finance
Cell therapy play Neogene’s $110M series A marks first investment for Tordjman’s Jeito Capital
Start-up Neogene has ties to Kite veterans Belldegrun, Chang
Items per page:
1 - 9 of 9